Johanna Olweus

Nedenfor liste over utvalgte publikasjoner.

Fullstendig publikasjonsliste her.

• Strønen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Böschen ML, Lund-Johansen F, Olweus J, Schumacher TN.Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016 May 19. pii: aaf2288. [Epub ahead of print] PMID: 27198675

• Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J. Sequential intranodal immuntherapy induces anti-tumor immunity and correlated regression of disseminated follicular lymphoma. Blood 2014 Oct 7 pii: blood-2014-07-592162. [Epub ahead of print]
• Kumari S, Walchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci U S A. 2014;111(1):403-408.
  Selected by Faculty of 1000 Prime:http://f1000.com/prime/718206020?bd=1 (Two stars)
• Lossius A, Johansen JN, Vartdal F, Robins H, Benth JS, Holmoy T, Olweus J. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8 T cells. Eur J Immunol. 2014.
• Walchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, . . . Olweus J*, Gregers TF*. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Eur J Immunol. 2014;44(3):774-784.
   *Shared senior authors. Front cover. Commentary in Eur J Immunol 2014, V44, p650
  Selected by Faculty of 1000 Prime: http://f1000.com/prime/718194774?bd=1&ui=28053
• Taraldsrud E, Fevang B, Aukrust P, Beiske KH, Floisand Y, Froland S, . . . Olweus J. Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9. 
  Clin Exp Immunol. 2014;175(3):439-448.
• Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Walchli S, Kumari S, . . . Olweus J. T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. Int J Cancer. 2012;130(8):1821-1832.
• Abrahamsen IW, Stronen E, Walchli S, Johansen JN, Kjellevoll S, Kumari S, . . . Olweus J. Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia. 2010;24(11):1901-1909.

• Nagel, Remco; Kochavi, Adva; Karlsen, Karine Flem; Adhikary, Mrittika; Gal-On, Yali & Klaoudatou, Maria G. [Vis alle 20 forfattere av denne artikkelen] (2026). Arginine Deprivation of ASS1-Deficient Cancers Drives Mistranslation and Shared Neoepitope Production. Cancer Research. ISSN 0008-5472. 86(14), s. 3480–3501. doi: 10.1158/0008-5472.CAN-25-4773. Fulltekst i vitenarkiv
• Douvlataniotis, Dimitrios Karolos; Titov, Aleksei; Zeun, Julia; Bilici, Merve; Palashati, Heyilimu & Loh, Waywen [Vis alle 23 forfattere av denne artikkelen] (2026). TCR T cells targeting IgA- and IgG-expressing multiple myeloma∗. Blood. ISSN 0006-4971. doi: 10.1182/blood.2025031897. Fulltekst i vitenarkiv Vis sammendrag

  T cell-based therapies have shown remarkable efficacy in multiple myeloma (MM), yet the disease remains largely incurable. Here, we investigated the constant domains of the immunoglobulin heavy chain (IgH) as novel targets for therapeutic T cell receptors (TCRs), after confirming high and homogeneous IGH expression in >95% of MM patients. MM cells secrete excessive monoclonal immunoglobulins (M-proteins) that drive complications but are inaccessible to CAR T-cell or antibody targeting. Peptides from IgA and IgG constant regions were eluted from HLA-A*02:01, and reactive TCRs were isolated from healthy donors using allo-HLA-A*02:01 presentation to circumvent self-tolerance. T cells engineered with two TCRs specific for IgA or IgG passed a stringent multi-tier safety screen and selectively eliminated MM cells from 20 HLA-A*02:01+ patients secreting the relevant IgH in vitro. In vivo, IgA-TCR T cells eradicated IgA+HLA-A*02:01+ MM cells in xenograft models and reduced circulating IgA in humanized mice. These findings establish immunoglobulin constant domains as viable TCR targets in MM, potentially making ~40% of patients of European descent eligible for TCR T cell therapy, and extension to additional HLA alleles could further broaden eligibility. The approach may also be applicable to lymphoma and antibody-mediated autoimmune diseases.

• Eggebø, Maria Stadheim; Heinzelbecker, Julia; Palashati, Heyilimu; Chandler, Nicholas John; Tran, Trung & Li, Yingqian [Vis alle 15 forfattere av denne artikkelen] (2025). TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors. Nature Immunology. ISSN 1529-2908. 26, s. 1726–1736. doi: 10.1038/s41590-025-02252-1. Fulltekst i vitenarkiv Vis sammendrag

  HLA-bound peptides encoded by recurrent driver mutations are candidate targets for T cell-directed immunotherapy. Here we identify two neopeptides encoded by the CTNNB1S37F mutation presented on the frequent HLA-A*02:01 and HLA-A*24:02 molecules in cell lines naturally expressing the mutation and HLA alleles. This mutation leads to a gain of function in β-catenin and is estimated to occur in >7,000 new cancer cases annually in the United States. T cell receptors (TCRs) that specifically recognize the mutant peptides were isolated from naive healthy donor T cells. T cells redirected with CTNNB1-S37F TCRs efficiently killed CTNNB1S37F+ cell lines and patient-derived organoids in vitro and eradicated established tumors in a melanoma cell line mouse model and a patient-derived xenograft model of endometrial adenocarcinoma naturally expressing the mutation and the restricting HLA. We propose that TCR-T cells targeting CTNNB1-S37F can serve as a basis for solid cancer immunotherapy.

• Rosenberger, Leonie; Hansmann, Leo; Anastasopoulou, Vasiliki; Wolf, Steven P; Drousch, Kimberley & Moewes, Christina [Vis alle 19 forfattere av denne artikkelen] (2025). Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. Journal for ImmunoTherapy of Cancer (JITC). 13(5). doi: 10.1136/jitc-2024-011351. Fulltekst i vitenarkiv Vis sammendrag

  Background The development of T-cell receptor (TCR)-based T-cell therapies is hampered by the difficulties in identifying therapeutically effective tumor-specific TCRs from the natural repertoire of a patient’s cancer-specific T cells. Methods Here, we mimic experimentally near-patient conditions to analyze the T-cell repertoire in euthymic tumor-bearing mice responding to the H-2Kb-presented neoantigen p68S551F (mp68). We temporarily separated the time point of mp68 expression from that of cancer cell transplantation to exclude the influence of injection-induced inflammation on T-cell priming. Thus, the mp68-specific T-cell response could only develop after the acute inflammatory phase had subsided. Results We found that mp68-specific TCRs isolated from either tumor-infiltrating T cells or spleens of mice immunized with mp68-expressing cancer cells are diverse and not inherently therapeutic when introduced into peripheral T cells and used for adoptive therapy of established tumors. While measuring short-term T-cell responses in vitro was unreliable for some TCRs in predicting their therapeutic failure, assessing the persistence of cancer cell destruction by TCR-modified T cells in long-term cultures accurately predicted therapeutic outcomes. A tumor-derived TCR with optimal function was also correctly identified with this approach when analyzing human TCRs that recognize the HLA-A2-presented neoantigen CDK4R24L. Conclusions We show that a neoantigen-directed T-cell response in tumor-bearing hosts comprises a diverse repertoire. Infiltration and expansion of certain T-cell clonotypes in the tumor do not necessarily correlate with therapeutic efficacy of their TCRs in adoptive therapy. We propose that analysis of persistent rather than immediate responses of TCR-modified T cells in vitro serves as a reliable parameter to identify TCRs that are therapeutically effective in vivo.

• Földvári, Zsofia; Brennan, Margs S.; Titov, Aleksei; Jacobsen, Sten Eirik W. & Olweus, Johanna (2025). Targeting the roots of myeloid malignancies with T cell receptors. Nature Reviews Cancer. ISSN 1474-175X. 25, s. 965–985. doi: 10.1038/s41568-025-00857-0. Fulltekst i vitenarkiv
• Weller, Chen; Bartok, Osnat; McGinnis, Christopher S.; Palashati, Heyilimu; Chang, Tian-Gen & Malko, Dmitry [Vis alle 47 forfattere av denne artikkelen] (2025). Translation dysregulation in cancer as a source for targetable antigens. Cancer Cell. ISSN 1535-6108. 43(5), s. 823–840. doi: 10.1016/j.ccell.2025.03.003. Fulltekst i vitenarkiv Vis sammendrag

  Aberrant peptides presented by major histocompatibility complex (MHC) molecules are targets for tumor eradication, as these peptides can be recognized as foreign by T cells. Protein synthesis in malignant cells is dysregulated, which may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies. To investigate the role of translational dysregulation in immunological tumor control, we disrupt translation fidelity by deleting tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterize the downstream impact on translation fidelity and immunogenicity using immunopeptidomics, genomics, and functional assays. These analyses reveal that TYW2 knockout (KO) cells generate immunogenic out-of-frame peptides. Furthermore, Tyw2 loss increases tumor immunogenicity and leads to anti-programmed cell death 1 (PD-1) checkpoint blockade sensitivity in vivo. Importantly, reduced TYW2 expression is associated with increased response to checkpoint blockade in patients. Together, we demonstrate that defects in translation fidelity drive tumor immunogenicity and may be leveraged for cancer immunotherapy.

• Mamia, Katariina Aino Inkeri; Kolbeinsdottir, Solrun; Labun, Kornel; Li, Zhuokun; Komisarczuk, Anna Zofia & Keskitalo, Salla [Vis alle 32 forfattere av denne artikkelen] (2025). Precision T cell correction platform for Inborn Errors of Immunity. Molecular Therapy. ISSN 1525-0016. 33(11), s. 5624–5643. doi: 10.1016/j.ymthe.2025.08.018. Fulltekst i vitenarkiv Vis sammendrag

  CRISPR/Cas9 gene editing is a promising tool to correct pathogenic variants for autologous cell therapies targeting Inborn errors of immunity (IEI). Current strategies, such as gene knockout or cDNA knock-in, address many single-gene defects but can disrupt gene expression, highlighting the need for precise correction platforms. While transplanting corrected autologous hematopoietic stem cells is a curative approach, it is unsuitable for patients with advanced disease, inflammation or acute infections. As correcting T cells is an alternative therapeutic strategy for lymphoid IEIs, we present an efficient T cell single nucleotide variant (SNV) correction platform based on homology-directed repair (HDR). By using STAT1 gain-of-function (STAT1-GOF), Cartilage Hair Hypoplasia (CHH), Deficiency of ADA2 (DADA2), and Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) as IEI models, we demonstrate that our platform achieves up to 80% correction, with resultant functional correction of the disease phenotype in the selected models. Furthermore, we performed safety profiling using GUIDE-seq, single-cell RNA sequencing, long-read genome sequencing, and proteomics analysis and detected no genomic, transcriptomic, or proteomic aberrations. This study establishes HDR-based SNV editing as a portable method for developing clinical autologous T cell therapies and represents a promising step toward a broad-spectrum gene correction platform for treating diverse monogenic immune disorders.

• Ma, J.; Meyer, Saskia; Olweus, Johanna; Jin, C. & Yu, D. (2025). An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products. Immuno-Oncology and Technology (IOTECH). 25. doi: 10.1016/j.iotech.2024.101031. Fulltekst i vitenarkiv
• Champagne, Julien; Nielsen, Morten Milek; Feng, Xiaodong; Navarro, Jasmine Montenegro; Pataskar, Abhijeet & Voogd, Rhianne [Vis alle 24 forfattere av denne artikkelen] (2025). Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity. ISSN 1074-7613. 58(1), s. 247–262.e9. doi: 10.1016/j.immuni.2024.12.004. Fulltekst i vitenarkiv Vis sammendrag

  Prolonged exposure to interferon-gamma (IFNγ) and the associated increased expression of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) create an intracellular shortage of tryptophan in the cancer cells, which stimulates ribosomal frameshifting and tryptophan to phenylalanine (W>F) codon reassignments during protein synthesis. Here, we investigated whether such neoepitopes can be useful targets of adoptive T cell therapy. Immunopeptidomic analyses uncovered hundreds of W>F neoepitopes mainly presented by the HLA-A∗24:02 allele. We identified a T cell receptor (TCRTMBIM6W>F.1) possessing high affinity and specificity toward TMBIM6W>F/HLA-A∗24:02, the inducible W>F neoepitope with the broadest expression across cancer cell lines. TCRTMBIM6W>F.1 T cells are activated by tryptophan-depleted cancer cells but not by non-cancer cells. Finally, we provide in vivo proof of concept for clinical application, whereby TCRMART1 T cells promote cancer cell killing by TCRTMBIM6W>F.1 T cells through the generation of W>F neoepitopes. Thus, neoepitopes arising from W>F substitution present shared and highly expressed immunogenic targets with the potential to overcome current limitations in adoptive T cell therapy.

• Tretbar, U. Sandy; Rurik, Joel G.; Rustad, Even Holth; Sürün, Duran; Köhl, Ulrike & Olweus, Johanna [Vis alle 10 forfattere av denne artikkelen] (2024). Non-viral vectors for chimeric antigen receptor immunotherapy. Nature Reviews Methods Primers. 4(1), s. 1–19. doi: 10.1038/s43586-024-00348-w. Fulltekst i vitenarkiv
• Földvári, Zsofia; Knetter, Cathrine; Yang, Weiwen; Gjerdingen, Thea Johanne; Bollineni, Ravi Chand & Tran, Trung [Vis alle 12 forfattere av denne artikkelen] (2023). A systematic safety pipeline for selection of T-cell receptors to enter clinical use. npj Vaccines. 8(1). doi: 10.1038/s41541-023-00713-y. Fulltekst i vitenarkiv
• Giannakopoulou, Eirini Chrysovalantou; Lehander, Madeleine; Culleton, Stina Virding; Yang, Weiwen; Li, Yingqian & Kärpänen, Terhi Hannele [Vis alle 29 forfattere av denne artikkelen] (2023). A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo. Nature Cancer. 4(10). doi: 10.1038/s43018-023-00642-8. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine kinase inhibitors has demonstrated that targeting of prevalent FMS-related receptor tyrosine kinase 3 (FLT3) gain-of-function mutations can provide significant survival benefits for patients, although the efficacy of FLT3 inhibitors in eliminating FLT3-mutated clones is variable. We identified a T cell receptor (TCR) reactive to the recurrent D835Y driver mutation in the FLT3 tyrosine kinase domain (TCR FLT3D/Y ). TCR FLT3D/Y -redirected T cells selectively eliminated primary human AML cells harboring the FLT3 D835Y mutation in vitro and in vivo. TCR FLT3D/Y cells rejected both CD34 + and CD34 − AML in mice engrafted with primary leukemia from patients, reaching minimal residual disease-negative levels, and eliminated primary CD34 + AML leukemia-propagating cells in vivo. Thus, T cells targeting a single shared mutation can provide efficient immunotherapy toward selective elimination of clonally involved primary AML cells in vivo.

• Spasevska, Ivana; Sharma, Ankush; Steen, Chloe Beate; Josefsson, Sarah Elisabet; Blaker, Yngvild Nuvin & Kolstad, Arne [Vis alle 26 forfattere av denne artikkelen] (2023). Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma. Blood Advances. ISSN 2473-9529. 7(23), s. 7216–7230. doi: 10.1182/bloodadvances.2023010158. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotypes and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Here, we applied single-cell RNA sequencing and T-cell receptor sequencing combined with high-dimensional cytometry to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma and follicular lymphoma (FL), compared with that in nonmalignant tonsillar tissue. We identified 3 distinct transcriptional states of Tregs: resting, activated, and unconventional LAG3+FOXP3− Tregs. Activated Tregs were enriched in B-NHL tumors, coexpressed several checkpoint receptors, and had stronger immunosuppressive activity compared with resting Tregs. In FL, activated Tregs were found in closer proximity to CD4+ and CD8+ T cells than other cell types. Furthermore, we used a computational approach to develop unique gene signature matrices, which were used to enumerate each Treg subset in cohorts with bulk gene expression data. In 2 independent FL cohorts, activated Tregs was the major subset, and high abundance was associated with adverse outcome. This study demonstrates that Tregs infiltrating B-NHL tumors are transcriptionally and functionally diverse. Highly immunosuppressive activated Tregs were enriched in tumor tissue but absent in the peripheral blood. Our data suggest that a deeper understanding of Treg heterogeneity in B-NHL could open new paths for rational drug design, facilitating selective targeting to improve antitumor immunity.

• Meyer, Saskia; Blaas, Isaac; Bollineni, Ravi Chand; Delic-Sarac, Marina; Tran, Trung & Knetter, Cathrine [Vis alle 20 forfattere av denne artikkelen] (2023). Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. Cell reports. 42(1). doi: 10.1016/j.celrep.2023.111995. Fulltekst i vitenarkiv Vis sammendrag

  The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell epitopes. However, studies on viral escape from T cell immunity have been hampered by uncertain estimates of epitope prevalence. Here, we map and quantify CD8 T cell responses to SARS-CoV-2-specific minimal epitopes in blood drawn from April to June 2020 from 83 COVID-19 convalescents. Among 37 HLA ligands eluted from five prevalent alleles and an additional 86 predicted binders, we identify 29 epitopes with an immunoprevalence ranging from 3% to 100% among individuals expressing the relevant HLA allele. Mutations in VOC are reported in 10.3% of the epitopes, while 20.6% of the non-immunogenic peptides are mutated in VOC. The nine most prevalent epitopes are conserved in VOC. Thus, comprehensive mapping of epitope prevalence does not provide evidence that mutations in VOC are driven by escape of T cell immunity.

• Pataskar, Abhijeet; Champagne, Julien; Nagel, Remco; Kenski, Juliana; Laos, Maarja & Michaux, Justine [Vis alle 24 forfattere av denne artikkelen] (2022). Tryptophan depletion results in tryptophan-to-phenylalanine substitutants. Nature. ISSN 0028-0836. 603(7902), s. 721–727. doi: 10.1038/s41586-022-04499-2. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Activated T cells secrete interferon-γ, which triggers intracellular tryptophan shortage by upregulating the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme 1–4 . Here we show that despite tryptophan depletion, in-frame protein synthesis continues across tryptophan codons. We identified tryptophan-to-phenylalanine codon reassignment (W>F) as the major event facilitating this process, and pinpointed tryptophanyl-tRNA synthetase (WARS1) as its source. We call these W>F peptides ‘substitutants’ to distinguish them from genetically encoded mutants. Using large-scale proteomics analyses, we demonstrate W>F substitutants to be highly abundant in multiple cancer types. W>F substitutants were enriched in tumours relative to matching adjacent normal tissues, and were associated with increased IDO1 expression, oncogenic signalling and the tumour-immune microenvironment. Functionally, W>F substitutants can impair protein activity, but also expand the landscape of antigens presented at the cell surface to activate T cell responses. Thus, substitutants are generated by an alternative decoding mechanism with potential effects on gene function and tumour immunoreactivity.

• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung & Delic-Sarac, Marina [Vis alle 22 forfattere av denne artikkelen] (2022). Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. ISSN 0007-1048. 197(6), s. 697–708. doi: 10.1111/bjh.18149. Fulltekst i vitenarkiv Vis sammendrag

  B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

• Bollineni, Ravi Chand; Tran, Trung; Lund-Johansen, Fridtjof & Olweus, Johanna (2022). Chasing neoantigens; invite naïve T cells to the party. Current Opinion in Immunology. ISSN 0952-7915. 75, s. 1–7. doi: 10.1016/j.coi.2022.102172. Fulltekst i vitenarkiv
• Mazzarella, Luca; Enblad, Gunilla; Olweus, Johanna; Malmberg, Karl-Johan & Jerkeman, Mats (2021). Advances in immune therapies in hematological malignancies. Journal of Internal Medicine. ISSN 0954-6820. s. 1–16. doi: 10.1111/joim.13395. Fulltekst i vitenarkiv Vis sammendrag

  Immunotherapy in cancer takes advantage of the exquisite specificity, potency, and flexibility of the immune system to eliminate alien tumor cells. It involves strategies to activate the entire immune defense, by unlocking mechanisms developed by tumor cells to escape from surrounding immune cells, as well as engineered antibody and cellular therapies. What is important to note is that these are therapeutics with curative potential. The earliest example of immune therapy is allogeneic stem cell transplantation, introduced in 1957, which is still an important modality in hematology, most notably in myeloid malignancies. In this review, we discuss developmental trends of immunotherapy in hematological malignancies, focusing on some of the strategies that we believe will have the most impact on future clinical practice in this field. In particular, we delineate novel developments for therapies that have already been introduced into the clinic, such as immune checkpoint inhibition and chimeric antigen receptor T-cell therapies. Finally, we discuss the therapeutic potential of emerging strategies based on T-cell receptors and adoptive transfer of allogeneic natural killer cells.

• Ali, Muhammad; Giannakopoulou, Eirini Chrysovalantou; Li, Yingqian; Lehander, Madeleine; Culleton, Stina Virding & Yang, Weiwen [Vis alle 33 forfattere av denne artikkelen] (2021). T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology. ISSN 1087-0156. doi: 10.1038/s41587-021-01089-x. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Unlike chimeric antigen receptors, T-cell receptors (TCRs) can recognize intracellular targets presented on human leukocyte antigen (HLA) molecules. Here we demonstrate that T cells expressing TCRs specific for peptides from the intracellular lymphoid-specific enzyme terminal deoxynucleotidyl transferase (TdT), presented in the context of HLA-A*02:01, specifically eliminate primary acute lymphoblastic leukemia (ALL) cells of T- and B-cell origin in vitro and in three mouse models of disseminated B-ALL. By contrast, the treatment spares normal peripheral T- and B-cell repertoires and normal myeloid cells in vitro, and in vivo in humanized mice. TdT is an attractive cancer target as it is highly and homogeneously expressed in 80–94% of B- and T-ALLs, but only transiently expressed during normal lymphoid differentiation, limiting on-target toxicity of TdT-specific T cells. TCR-modified T cells targeting TdT may be a promising immunotherapy for B-ALL and T-ALL that preserves normal lymphocytes.

• Ask, Eivind Heggernes; Tschan-Plessl, Astrid; Gjerdingen, Thea Johanne; Hoel, Hanna Julie; Sætersmoen, Michelle Lu & Wiiger, Merete Thune [Vis alle 16 forfattere av denne artikkelen] (2021). A Systemic Protein Deviation Score Linked to PD-1+ CD8+ T Cell Expansion That Predicts Overall Survival in Diffuse Large B Cell Lymphoma. Med. ISSN 2666-6359. 2(2), s. 180–195. doi: 10.1016/j.medj.2020.10.006. Fulltekst i vitenarkiv
• Bartok, Osnat; Pataskar, Abhijeet; Nagel, Remco; Laos, Maarja; Goldfarb, Eden & Hayoun, Deborah [Vis alle 30 forfattere av denne artikkelen] (2020). Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature. ISSN 0028-0836. 590, s. 332–337. doi: 10.1038/s41586-020-03054-1. Fulltekst i vitenarkiv
• Muhammad, Ali; Földvári, Zsofia; Giannakopoulou, Eirini Chrysovalantou; Bøschen, Maxi-Lu; Strønen, Erlend & Yang, Weiwen [Vis alle 11 forfattere av denne artikkelen] (2019). Induction of neoantigen-reactive T cells from healthy donors. Nature Protocols. ISSN 1754-2189. 14(6), s. 1926–1943. doi: 10.1038/s41596-019-0170-6. Fulltekst i vitenarkiv
• Oei, Vincent Yi Sheng; Siernicka, Marta; Graczyk-Jarzynka, Agnieszka; Hoel, Hanna Julie; Yang, Weiwen & Orellana, Daniel Alfredo Palacios [Vis alle 17 forfattere av denne artikkelen] (2018). Intrinsic functional potential of NK-Cell subsets constrains retargeting driven by chimeric antigen receptors. Cancer immunology research. ISSN 2326-6066. 6(4), s. 467–480. doi: 10.1158/2326-6066.CIR-17-0207. Fulltekst i vitenarkiv Vis sammendrag

  Natural killer (NK) cells hold potential as a source of allogeneic cytotoxic effector cells for chimeric antigen receptor (CAR)-mediated therapies. Here, we explored the feasibility of transfecting CAR-encoding mRNA into primary NK cells and investigated how the intrinsic potential of discrete NK-cell subsets affects retargeting efficiency. After screening five second- and third-generation anti-CD19 CAR constructs with different signaling domains and spacer regions, a third-generation CAR with the CH2-domain removed was selected based on its expression and functional profiles. Kinetics experiments revealed that CAR expression was optimal after 3 days of IL15 stimulation prior to transfection, consistently achieving over 80% expression. CAR-engineered NK cells acquired increased degranulation toward CD19+ targets, and maintained their intrinsic degranulation response toward CD19− K562 cells. The response of redirected NK-cell subsets against CD19+ targets was dependent on their intrinsic thresholds for activation determined through both differentiation and education by killer cell immunoglobulin-like receptors (KIR) and/or CD94/NKG2A binding to self HLA class I and HLA-E, respectively. Redirected primary NK cells were insensitive to inhibition through NKG2A/HLA-E interactions but remained sensitive to inhibition through KIR depending on the amount of HLA class I expressed on target cells. Adaptive NK cells, expressing NKG2C, CD57, and self-HLA–specific KIR(s), displayed superior ability to kill CD19+, HLA low, or mismatched tumor cells. These findings support the feasibility of primary allogeneic NK cells for CAR engineering and highlight a need to consider NK-cell diversity when optimizing efficacy of cancer immunotherapies based on CAR-expressing NK cells.

• Kärpänen, Terhi Hannele & Olweus, Johanna (2017). The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. Frontiers in Immunology. doi: 10.3389/fimmu.2017.01718. Fulltekst i vitenarkiv Vis sammendrag

  T cells can recognize peptides encoded by mutated genes, but analysis of tumor-infiltrating lymphocytes suggests that very few neoantigens spontaneously elicit T-cell responses. This may be an important reason why immune checkpoint inhibitors are mainly effective in tumors with a high mutational burden. Reasons for clinically insufficient responses to neoantigens might be inefficient priming, inhibition, or deletion of the cognate T cells. Responses can be dramatically improved by cancer immunotherapy such as checkpoint inhibition, but often with temporary effects. By contrast, T cells from human leukocyte antigen (HLA)-matched donors can cure diseases such as chronic myeloid leukemia. The therapeutic effect is mediated by donor T cells recognizing polymorphic peptides for which the donor and patient are disparate, presented on self-HLA. Donor T-cell repertoires are unbiased by the immunosuppressive environment of the tumor. A recent study demonstrated that T cells from healthy individuals are able to respond to neoantigens that are ignored by tumor-infiltrating T cells of melanoma patients. In this review, we discuss possible reasons why neoantigens escape host T cells and how these limitations may be overcome by utilization of donor-derived T-cell repertoires to facilitate rational design of neoantigen-targeted immunotherapy.

• Taraldsrud, Eli; Fevang, Børre; Jørgensen, Silje Fjellgård; Moltu, Kristine; Hilden, Vera Irene & Tasken, Kjetil [Vis alle 9 forfattere av denne artikkelen] (2017). Defective IL-4 signaling in T cells defines severe common variable immunodeficiency. Journal of Autoimmunity. ISSN 0896-8411. 81, s. 110–119. doi: 10.1016/j.jaut.2017.04.004. Fulltekst i vitenarkiv
• Henriksen, Eva Kristine Klemsdal; Jørgensen, Kristin Kaasen; Kaveh, Fatemeh; Holm, Kristian; Hamm, David & Olweus, Johanna [Vis alle 14 forfattere av denne artikkelen] (2017). Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. Journal of Hepatology. ISSN 0168-8278. 66(1), s. 116–122. doi: 10.1016/j.jhep.2016.09.002. Fulltekst i vitenarkiv
• Olweus, Johanna (2017). Manufacture of CAR-T cells in the body. Nature Biotechnology. ISSN 1087-0156. 35(6), s. 520–521. doi: 10.1038/nbt.3898. Fulltekst i vitenarkiv
• Taraldsrud, Eli; Aukrust, Pål; Jørgensen, Silje Fjellgård; Lingjærde, Ole Christian; Olweus, Johanna & Myklebust, June [Vis alle 7 forfattere av denne artikkelen] (2017). Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency. Clinical Immunology. ISSN 1521-6616. 175, s. 69–74. doi: 10.1016/j.clim.2016.11.014. Fulltekst i vitenarkiv Vis sammendrag

  Patients with common variable immunodeficiency (CVID) constitute a clinically and immunologically heterogeneous group characterized by B-cell dysfunction with hypogammaglobulinemia and defective immunoglobulin class switch of unknown etiology. Current classification systems are insufficient to achieve precise disease management. Characterization of signaling pathways essential for B-cell differentiation and class switch could provide new means to stratify patients. We evaluated constitutive and induced signaling by phospho-specific flow cytometry in 26 CVID patients and 18 healthy blood donors. Strong responses were induced both in CVID and healthy donor B cells upon activation. In contrast, constitutive phosphorylation levels of STAT3,-5,-6, Erk, PLC-γ and Syk were significantly increased in CVID B cells only. Hierarchical clustering revealed a subgroup of CVID patients with elevated constitutive phosphorylation of Syk and PLC-γ. All these patients had non-infectious complications, indicating that a distinct phosphorylation pattern of kinases in B cells identifies a clinically important subgroup of CVID patients.

Se alle arbeider i NVA

• Gjerdingen, Thea Johanne; Meyer, Saskia; Weis-Banke, Stine Emilie; Hansen, Marie; Ma, Jing & Yu, Di [Vis alle 13 forfattere av denne artikkelen] (2026). InsighT-1: Translating an academic TCR program into a GMP-compliant cell therapy for TdT+ ALL/LBL. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). TV 2 Direkte. [TV]. TV2. doi: https:/play.tv2.no/direkte-tv/tv-2-direkte-as9ka55m?play=true. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). NRK Nyheter: 19 mai kl. 14:00. Sak: Kongen delte ut kreftforsknignspris til Professor Johanna Olweus ved Universitetet i Oslo. [TV]. NRK. doi: https:/tv.nrk.no/serie/nyheter/sesong/202605/episode/NNFA14051926. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). NRK Nyheter: 19 mai kl. 15:00. Sak: Kongen delte ut kreftforsknignspris til Professor Johanna Olweus ved Universitetet i Oslo. [TV]. NRK. doi: https:/tv.nrk.no/serie/nyheter/sesong/202605/episode/NNFA15051926. Fulltekst i vitenarkiv
• Briceño, Laurita Fure & Olweus, Johanna (2026). Oliver blei kreftfri på ti dagar – forskar som vidareutviklar behandlinga får gjæv pris. doi: https:/www.nrk.no/vestland/oliver-blei-kreftfri-pa-ti-dagar-_-no-far-forskaren-gjev-pris-1.17880611. Fulltekst i vitenarkiv
• Bergseng, Anne & Olweus, Johanna (2026). Oliver (17): –⁠ Jeg fikk livet tilbake. doi: https:/www.vg.no/helse/i/0p9OJo/oliver-17-ble-frisk-med-ny-kreftbehandling. Fulltekst i vitenarkiv
• Anderssen, Hans & Olweus, Johanna (2026). Johanna Olweus får Kong Olav Vs kreftforskningspris: Vil flytte celleterapi fra blodkreft til solide svulster. doi: https:/www.healthtalk.no/kreft/johanna-olweus-far-kong-olav-vs-kreftforskningspris-vil-flytte-celleterapi-fra-blodkreft-til-solide-svulster/211314. Fulltekst i vitenarkiv
• Blekkerud, Martin & Olweus, Johanna (2026). – Jeg er nok litt besatt. doi: https:/kreftforeningen.no/aktuelt/jeg-er-nok-litt-besatt/. Fulltekst i vitenarkiv
• Blekkerud, Martin & Olweus, Johanna (2026). Johanna Olweus får Olav Vs kreftforskningspris. doi: https:/www.oslo-universitetssykehus.no/om-oss/nyheter/kreftforskningspris-til-johanna-olweus/. Fulltekst i vitenarkiv
• Kvaal, Julie Nybakk & Olweus, Johanna (2026). Kong Olav Vs Kreftforskningspris til professor Johanna Olweus. doi: https:/www.med.uio.no/klinmed/om/aktuelt/aktuelle-saker/2026/kong-olav-kreftforskningspris-til-professor-johanna-olweus.html. Fulltekst i vitenarkiv
• Ingebrigtsen, Julia Renate & Olweus, Johanna (2026). Nytt våpen mot kreft: Sender en «armé» inn i kroppen. doi: https:/www.vg.no/helse/i/0pL0gg/nytt-vaapen-mot-kreft-sender-en-arme-inn-i-kroppen. Fulltekst i vitenarkiv
• Nymoen, Ole Christian & Olweus, Johanna (2026). Over 800 nordmenn dør årlig av krefttypen: Forskere med gjennombrudd. doi: https:/www.nettavisen.no/nyheter/bukspyttkjertelkreft-forskere-kan-ha-funnet-behandling/s/5-95-2860961. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). From TCR discovery to the clinic - about not getting lost in translation. Fulltekst i vitenarkiv
• Olweus, Johanna & Andersen, Jan Terje (2026). Debatt: Mange lovende teknologier stopper før de når pasienten. doi: https:/medwatch.no/nyheter/debatt/article19532426.ece. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Targeting multiple myeloma with T cells expressing therapeutic T-cell receptors. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Targeting cancer with T-cell receptors. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Targeting hematological cancers with T cells expressing therapeutic T-cell receptors. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Targeting hematological cancers with T cells expressing therapeutic T-cell receptors. Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Hvordan målrette immunforsvaret mot kreft? Fulltekst i vitenarkiv
• Olweus, Johanna (2026). Morgendagens presisjons-immunterapi mot blodkreft. Fulltekst i vitenarkiv
• Gjerdingen, Thea Johanne; Meyer, Saskia; Weis-Banke, Stine Emilie; Hansen, Marie; Ma, Jing & Yu, Di [Vis alle 13 forfattere av denne artikkelen] (2026). INSIGHT-1: TRANSLATING AN ACADEMIC TCR PROGRAM INTO A GMP-COMPLIANT CELL THERAPY FOR TdT+ ALL/LBL. Cytotherapy. ISSN 1465-3249. 28(5), s. 102861–102861. doi: 10.1016/j.jcyt.2026.102861. Fulltekst i vitenarkiv
• Palashati, Heyilimu; Flem-Karlsen, Karine; Heinzelbecker, Julia; Eggebø, Maria Stadheim; Chandler, Nicholas John & Yang, W [Vis alle 10 forfattere av denne artikkelen] (2026). P02.12 Identification of an HLA-A*11:01-restricted KRASG12V-specific T cell receptor with strong antitumor responses in patient-derived cancer models. Journal for ImmunoTherapy of Cancer (JITC). 14(Suppl 1). doi: 10.1136/jitc-2026-itoc.26. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Immunceller kan bli leiemordere som dreper kreft. doi: https:/www.med.uio.no/om/aktuelt/blogg/2025/immunceller-kan-bli-leiemordere-som-dreper-kreft.html. Fulltekst i vitenarkiv
• Sjøgren, Kristian & Olweus, Johanna (2025). Guided immune cells make tumours disappear without a trace. doi: https:/sciencenews.dk/en/guided-immune-cells-make-tumours-disappear-without-a-trace. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Norsk team med stort gjennombrudd innen kreftforskning. [TV]. TV 2. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Groundbreaking study attracts attention. doi: https:/ous-research.no/home/institute/Homepage%20news/26407. Fulltekst i vitenarkiv
• Kvaal, Julie Nybakk & Olweus, Johanna (2025). Ny immunterapi gir håp mot lungekreft og prostatakreft. doi: https:/www.uio.no/forskning/forskningsnytt/artikler/2025/ny-immunterapi-gir-hap-mot-lungekreft-og-prostatakreft.html. Fulltekst i vitenarkiv
• Bergseng, Anne & Olweus, Johanna (2025). Norsk kreftstudie: –⁠ Dette er absolutt et gjennombrudd. doi: https:/www.vg.no/helse/i/0VMW9o/norsk-gjennombrudd-innen-kreftforskning-mulighet-for-aa-behandle-flere-aggressive-kreftformer. Fulltekst i vitenarkiv
• Olweus, Johanna & Andersen, Jan Terje (2025). Målrettet kreftbehandling. Proteiner og betydningen av fjorårets Nobelpris i kjemi. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Fremtidens kreftbehandling. doi: https:/www.youtube.com/watch?v=BqrXPhGJrBk&t=369s. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Kreftbehandling ved genterapi: målstyrte immunceller. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Targeting hematological malignancies with T-cell receptors. doi: https:/2024.ehaweb.org/congress/eha2025-congress/. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Broadening the range of therapeutic targets using T-cell receptors. doi: https:/www.uantwerpen.be/en/conferences/antwerp-tcr-conference-2025/. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Expanding the repertoire of therapeutic targets in myeloid malignancies with TCRs. doi: https:/www.fusion-conferences.com/conference/180. Fulltekst i vitenarkiv
• Olweus, Johanna (2025). Targeting cancer with T-cell receptor-engineered T cells. doi: https:/lymphocyte.kenes.com/. Fulltekst i vitenarkiv
• Olweus, Johanna & Andersen, Jan Terje (2025). Målrettet kreftbehandling med KI. YouTube. doi: https:/www.bioteknologiradet.no/arrangement/bioteknologidagen-2025/. Fulltekst i vitenarkiv
• Haugen, Frida Loe; Mamia, Katariina Aino Inkeri; Rio, Oline Eriksen; Sollano, Anniken Solveig Matheson; Li, Zhuokun & Labun, Kornel [Vis alle 20 forfattere av denne artikkelen] (2025). CRISPR/Cas9-based pipeline to introduce custom edits in autologous T cells. Fulltekst i vitenarkiv
• Olweus, Johanna & Lund-Johansen, Fridtjof (2025). T cells engineered to target a shared β-catenin mutation eradicate solid tumors in mice. Nature Immunology. ISSN 1529-2908. doi: 10.1038/s41590-025-02287-4. Fulltekst i vitenarkiv
• Haugen, Frida Loe; Mamia, Katariina Aino Inkeri; Rio, Oline Eriksen; Sollano, Anniken Solveig Matheson; Li, Zhuokun & Labun, Kornel [Vis alle 20 forfattere av denne artikkelen] (2025). CRISPR-Cas9 pipeline for custom editing in autologous T cells. doi: https:/event.fourwaves.com/crisprmed25/abstracts/b5911e8e-de8e-4ee4-b8e2-9f08cc2f31d8. Fulltekst i vitenarkiv Vis sammendrag

  CRISPR/Cas9 gene editing technology is a promising tool for correcting pathogenic variants in Inborn Errors of Immunity (IEIs). Current IEI correction strategies rely on cDNA knock-in or gene knockout, which can disrupt gene expression and need extensive optimization. To address this, we developed a safe, efficient CRISPR/Cas9-based T cell editing pipeline using HDR for SNV correction. We observe a rapid and selective expansion of CD3+ T cells from patient peripheral blood following an 8-day cytokine stimulation. To enhance HDR outcomes, we explored multiple strategies and developed an optimized T cell pipeline capable of achieving up to 80% HDR. We found no pre-malignant off-target effects or karyotypic, transcriptomic, or proteomic abnormalities in patient T cells analysed with GUIDE-seq, scRNA-seq, long-read WGS, and proteomics. We observed functional correction of the disease phenotype in patient T cells demonstrated on transcriptomic level by single cell RNA sequencing, on proteomic level by Mass Spectrometry and in cell culture-based assays. So far, we have implemented the pipeline and corrected 12 unique SNV mutations causing 8 diverse IEIs. This platform is designed to streamline CRISPR tool discovery/optimization and can be further developed into a GMP-compatible, scaled-up process for salvage therapy in T cell-related IEIs.

• Olweus, Johanna (2024). T-cell receptors in cancer immunotherapy: New opportunities. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). New cancer-specific antigens and targeting of intracellular antigens. Fulltekst i vitenarkiv
• Mamia, Katariina Aino Inkeri; Kolbeinsdottir, Solrun; Li, Zhuokun; Reint, Ganna; Komisarczuk, Anna Zofia & Haugen, Frida Høsøien [Vis alle 21 forfattere av denne artikkelen] (2024). CRISPR/Cas9 T cell editing pipeline for monogenic primary immunodeficiency disorders. Fulltekst i vitenarkiv
• Mamia, Katariina Aino Inkeri; Kolbeinsdottir, Solrun; Li, Zhuokun; Reint, Ganna; Komisarczuk, Anna Zofia & Haugen, Frida Høsøien [Vis alle 21 forfattere av denne artikkelen] (2024). CRISPR/Cas9 T cell editing pipeline for monogenic primary immunodeficiency disorders. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Opportunities for T-cell receptors in cancer immunotherapy. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Opportunities for T-cell receptors in cell therapy: OUH research in PRIMA and beyond. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Mining healthy donor T cell repertoires to identify the right T-cell receptor (TCR) for the right patient. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Mining healthy donor T cell repertoires to identify the right T-cell receptor (TCR) for the right patient. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Økt legemiddelproduksjon i Norge innen celleterapi - hvor skal vi starte? Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Mining broad T cell repertoires to identify T-cell receptors to new targets. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Outsourcing cancer immunity to healthy donors. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Epitope editing shields healthy blood cells from immunotherapies. [Internet]. Drug Discovery News (DDN). Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Johanna Olweus and her research group first in the Nordics to be on team selected for Cancer Grand Challenges funding. [Internet]. ous-research.no. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Forskere vil bruke KI i kampen mot kreft og andre sykdommer. [Internet]. forskning.no. Fulltekst i vitenarkiv
• Olweus, Johanna & Nielsen, Morten Milek (2024). The use of T cell receptors (TCR’s) as immunotherapy against cancer. [Radio]. The Cell Therapy podcast (Spotify). Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Opportunities for T-cell receptors in cancer immunotherapy. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Next-generation CAR and TCR Cancer Therapies. [Internet]. The Scientist. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Finding the right T-cell receptor for the right patient. Fulltekst i vitenarkiv
• Mamia, Katariina Aino Inkeri; Kolbeinsdottir, Solrun; Li, Zhuokun; Reint, Ganna; Komisarczuk, Anna Zofia & Haugen, Frida Høsøien [Vis alle 21 forfattere av denne artikkelen] (2024). CRISPR/Cas9 T cell editing pipeline for monogenic primary immunodeficiency disorders. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Opportunities for T-cell receptors in cancer immunotherapy. Fulltekst i vitenarkiv
• Olweus, Johanna (2024). Til krig mot kreft i sønnens navn. [Journal]. VG. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). T-cell receptor – target pairs that provide new therapeutic opportunities in cancer. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). How can we use TCRs in incurable MDS? Fulltekst i vitenarkiv
• Olweus, Johanna (2023). Finding safe and effective T cell receptors for the next generation cancer immunotherapies. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). New categories of shared antigens for TCR T cell therapies. Fulltekst i vitenarkiv
• Tasken, Kjetil; Olweus, Johanna & Røttingen, John-Arne (2023). Årets nobelpris i medisin viser hvor tett koblingen må være mellom forskning, innovasjon og anvendelse. –Om mRNA som infeksjonsforebygging og kreftbehandling (Kronikk). [Journal]. Aftenposten. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). Possible new treatment for leukemia. [Internet]. University of Oslo website. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). A new marching order for the T cell army in the attack of AML. [Internet]. ACIR. Fulltekst i vitenarkiv
• Olweus, Johanna (2023). Mulig ny behandling for blodkreft. [Internet]. forskning.no. Fulltekst i vitenarkiv
• Tasken, Kjetil; Olweus, Johanna & Røttingen, John-Arne (2023). Om mRNA som infeksjonsforebygging og kreftbehandling. Fulltekst i vitenarkiv
• Mamia, Katariina Aino Inkeri; Saarela, Janna Saija; Li, Zhuokun; Reint, Ganna; Fatkhutdinov, Nail & Haugen, Frida Høsøien [Vis alle 13 forfattere av denne artikkelen] (2022). CRISPR-Cas9 T cell editing pipeline for Finnish founder diseases. Fulltekst i vitenarkiv
• Pataskar, Abhijeet; Champagne, Julien; Nagel, Remco; Kenski, Juliana; Laos, Maarja & Michaux, Justine [Vis alle 24 forfattere av denne artikkelen] (2022). Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants (Nature, (2022), 603, 7902, (721-727), 10.1038/s41586-022-04499-2). Nature. ISSN 0028-0836. doi: 10.1038/s41586-022-05097-y. Fulltekst i vitenarkiv
• Olweus, Johanna & Lund-Johansen, Fridtjof (2019). Finding Neo (antigens, that is). Blood. ISSN 0006-4971. 134(2), s. 108–109. doi: 10.1182/blood.2019001334. Fulltekst i vitenarkiv

Se alle arbeider i NVA